Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neurofibroma, Plexiform 3Neurofibromatosis 1 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Radiation Fibrosis Syndrome 1Precancerous Conditions 1Pneumonia 1Neurofibromatoses 1Nerve Sheath Neoplasms 1Neoplasms 1Myofibroma 1Lymphedema 1Leiomyoma 1Colorectal Neoplasms 1Acute Lung Injury 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × pirfenidone × Clear all
NCT05280873 2022-03-15

Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP

Guangzhou Institute of Respiratory Disease

Phase 1 Unknown
48 enrolled

Neoplasms, Pneumonia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡